Celgene Corp

Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.

According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.

Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

In Q3 2019, Citadel Advisors’ portfolio of publicly traded securities was worth $212.04 billion. In Q2 2019, its portfolio was worth $155.1 billion.

In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.

On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.

According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.

In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.

Celgene (CELG) is focused on advancing its diversified inflammation and immunology (or I&I) research pipeline in 2018.

On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.

In 1Q18, Celgene’s (CELG) revenue grew 20% year-over-year to $3.5 billion from $3.0 billion, boosted by Revlimid, Pomalyst, and Otezla sales.

Kymriah is the first FDA-approved chimeric antigen receptor T cell (or CAR-T) therapy.

The National Cancer Institute estimates that the incidence of ALL in patients aged 20 or younger is ~3,100 in the US.

In 2018, GlaxoSmithKline aims to initiate a pivotal phase 2 trial to evaluate GSK 916 as monotherapy Darzalex refractory population as the fourth line or the last line of multiple myeloma therapy.

On January 22, 2018, Celgene and Juno Therapeutics announced a merger agreement in which the former will acquire the latter’s business.

In December 2017, Novartis presented the results from the post-hoc subgroup analysis of the phase 2 Sustain trial.

In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.

In July 2017, the US FDA (Food and Drug Administration) approved Johnson & Johnson’s (JNJ) Tremfya (guselkumab) for the treatment of individuals with moderate to severe plaque psoriasis.

EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.

Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”

In August 2017, JAZZ’s Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.

On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.

Orencia revenues rose to $650.0 million in 2Q17, a 10.0% rise compared to $593 million in 2Q16.

Bristol-Myers Squibb (BMY) surpassed Wall Street analysts’ estimate for 2Q17 revenues, reporting $5.14 billion compared to the estimate of $5.09 billion.

Defitelio could help Jazz Pharmaceuticals become a prominent player not only in the treatment but also in the prevention of post-HSCT complications.

In early 2017, Jazz Pharmaceuticals (JAZZ) expanded its sales force team from 35 to 55 and expanded its field reimbursement teams to support the commercial launch of Vyxeos in the US.

If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.

Jazz Pharmaceuticals (JAZZ) expects quarterly variability in Defitelio sales as the drug targets hepatic veno-occlusive disease (or VOD), an ultra-rare condition.

For 2Q17, Jazz Pharmaceuticals (JAZZ) reported revenues close to $394 million, which represented a YoY growth of ~3% and sequential growth ~5%.

The Phase 3 RADIANCE trial enrolled 1,313 RMS patients and conducted the trial in 21 countries.

In 2Q17, Celgene’s (CELG) Abraxane generated revenues of around $254 million, which reflected ~2% growth on a year-over-year basis.

In 2Q17, Celgene’s (CELG) Revlimid generated revenues of ~$2.0 billion, which reflected ~20% growth year-over-year and ~8% growth quarter-over-quarter.

Eli Lilly’’s (LLY) Human Pharmaceuticals segment reported a rise of ~11.0% to ~$5.0 billion for 2Q17 compared to ~$4.6 billion for 2Q16.

Pfizer (PFE) is extensively conducting clinical trials for the label expansion of Ibrance.

Allergan Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on generic and specialty pharmaceutical products. The company has divided its business into three segments: US Specialized Therapeutics, US General Medicine, and International. Stock price performance Allergan’s stock price has risen ~1.4% in 2Q17, and 15.0% year-to-date as of July 7, 2017. […]

Follow-up data were released from the Checkmate-205 study. It evaluated long-term effects of PD-1 inhibitors in patients with classical Hodgkin Lymphoma.

AbbVie (ABBV) has a focused immunology pipeline in order to address various dermatologic and gastrointestinal conditions.

Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.

The S&P 500 Index (SPX-INDEX) has posted a rise of ~5% since the beginning of 2017, with banks and energy stocks leading the rally as of March 29, 2017.

For 2016, AstraZeneca (AZN) reported revenues of about $5.8 billion for its emerging markets business, which is a YoY (year-over-year) rise of about 6.0%.

AbbVie’s (ABBV) Venclexta has been granted FDA breakthrough therapy designation as a first line therapy for patients with acute myeloid leukemia who are ineligible for high-dose chemotherapy.